Autifony Therapeutics receives Orphan Drug Designation for AUT00206 for Fragile X Syndrome

Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced that the U.S. Food and Drug Administration…
Read More